Published by
@ShahidNShah
@ShahidNShah
FDA grants De Novo clearance to smartphone-controlled acute migraine-relief device
Theranica, an Israel-based biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases, announced on May 28 that the U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra®, utilising Remote Electrical Neuromodulation for the acute treatment of migraine.
Continue reading at mobihealthnews.com
Make faster decisions with community advice
- Google vet Roni Zeiger leaves Smart Patients to head up Facebook's growing health efforts
- The high cost of physician burnout: $4.6B a year
- We need to be strategic as digital technology transforms oncology
- OIG: Medicare ACOs have yet to realize full potential of health IT
- RaDaR Aims to Help Patient Groups Develop Rare Disease Registries
Next Article
-
Google vet Roni Zeiger leaves Smart Patients to head up Facebook's growing health efforts
Zeiger quietly announced the news in a post on his own blog entitled “An Opportunity I Can’t Resist.” Based on that short post, it appears that Facebook’s recently launched Health …
Posted May 29, 2019digital health leadership
